Core Viewpoint - Zhonghui Biotech-B (02627) expects to achieve approximately RMB 446 million to RMB 493 million in revenue for the fiscal year 2025, representing an increase of about 71.8% to 89.9% compared to RMB 260 million in revenue for the year ending December 31, 2024. The company anticipates a net loss of approximately RMB 157 million to RMB 197 million for the same period, a reduction of about 23.9% to 39.3% from a net loss of RMB 259 million for the previous year [1] Group 1 - The increase in revenue and reduction in net loss are primarily attributed to the continuous enhancement of the company's quality management system, which ensures a 100% product quality approval rate, thereby lowering sales costs [1] - The implementation of digital precision marketing strategies, including real-time visualization of sales data and targeted marketing policies, has improved the efficiency of marketing expenses while supporting revenue growth [1] - The company has expanded its product delivery to cover 232 disease control centers and 2,563 vaccination clinics, providing more regional options for consumers and directly driving revenue growth [1] Group 2 - Despite a significant increase in listing expenses for 2025, the combined effect of revenue growth and tightened cost control has led to a further narrowing of the net loss for the fiscal year [1]
中慧生物-B(02627)预计年度营业收入约4.46亿元至4.93亿元 同比增加约71.8%至89.9%